leadf
logo-loader
viewGenprex, Inc.

Full interview: Genprex's newly licensed type 1 diabetes gene therapy's potential explained by scientist

Dr George Gittes, Professor of Surgery at the Children's Hospital of Pittsburgh explains how and why he began working on the gene therapy licensed by Genprex (NASDAQ:GNPX).

Dr Gittes says the therapy, currently undergoing pre-clinical studies, has shown data where it caused pancreatic cells to turn into insulin-producing cells.

Quick facts: Genprex, Inc.

Price: 3.27 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $127.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

FenixOro Gold continues aggressive drill program at their Abriaqui Project...

FenixOro Gold (CSE: FENX-OTCQB: FDVXF) CEO John Carlesso joined Steve Darling from Proactive to bring details about their drilling program that is ongoing at their gold silver and copper project in Colombia. That project is called Abriaqui and sits along a very mineralized belt. Carlesso...

in 2 hours, 37 minutes

2 min read